The role of Testosterone Therapy (TTh) in the management of male sexual dysfunction remains unclear. Objective of the authors was to systematically review the relevant literature assessing the benefits and harms of TTh in men with sexual dysfunction. EMBASE, MEDLINE, Cochrane Systematic Reviews—Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane HTA, DARE, HEED), Google Scholar, WHO international Clinical Trials Registry Platform Search Portal, CINAHL databases and clinicaltrial.gov were searched systematically in March 2015 and an updated search was performed in March 2016. Randomized and non-randomized comparative studies assessing the benefits and harms of TTh in hypogonadal, borderline eugonadal and eugonadal men suffering from sexual dysfunction were included. Risk of bias and confounding assessments were performed. A narrative synthesis was undertaken. Of the 6410 abstracts identified, 36 studies were judged to be eligible for inclusion, including 25 randomized clinical trials (RCTs) and 11 non-randomized comparative studies (NRCSs), recruiting a total of 4944 patients. RCTs were judged to have low or unclear risk of bias, while NRCSs had high risk of bias and thus, overall quality of evidence was judged to be at least unclear. Based on the evidence mainly provided by the RCTs included in this systematic review, TTh could be considered for men with low or low-normal testosterone levels and problems with their sexual desire, erectile function and satisfaction derived from intercourse and overall sexual life. The exact testosterone formulation, dosage and duration of treatment remain to be clarified, while the safety profile of TTh also remains unclear. TTh could be used with caution in hypogonadal and most probably borderline eugonadal men to manage disorders of sexual desire, erectile function and sexual satisfaction. The overall low-to-moderate evidence quality highlights the need for robust and adequately designed clinical trials.

睾丸激素疗法（TTh）在男性性功能障碍管理中的作用尚不清楚。作者的目的是系统地复习有关评估TTH在性功能障碍男性中的利弊的文献。EMBASE，MEDLINE，Cochrane系统评价-2015年3月，系统地搜索了Cochrane对照试验中央注册系统（CENTRAL）（Cochrane HTA，DARE，HEED），Google Scholar，WHO国际临床试验注册平台搜索门户，CINAHL数据库和Clinicaltrial.gov。并在2016年3月进行了更新搜索。纳入了TTH在性功能障碍的性腺功能减退，交界性性腺和性腺性男性中的利弊的随机和非随机对照研究。进行偏见风险和混杂评估。进行了叙事综合。在确定的6410篇摘要中，有36项研究被判定为合格，包括25项随机临床试验（RCT）和11项非随机比较研究（NRCS），共招募了4944例患者。RCT被认为具有较低或不清楚的偏倚风险，而NRCS则具有较高的偏倚风险，因此，总体证据质量被判断为至少不清楚。根据该系统评价中主要由RCT提供的证据，可以考虑将TTh用于睾丸激素水平偏低或偏低以及性欲，勃起功能和性生活和性生活总体满意度引起的问题的男性。确切的睾丸激素配方，剂量和治疗时间有待澄清，而TTh的安全性也不清楚。在性腺机能减退者和最可能是边缘性的性腺感染者中，应谨慎使用TTh，以控制性欲，勃起功能和性满足的疾病。总体中低至中等的证据质量凸显了对稳健且设计合理的临床试验的需求。